ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)

[1]  T. Stankovic,et al.  ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. , 2016, Blood.

[2]  M. Grever,et al.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997 , 2015, Leukemia & lymphoma.

[3]  Y. Shiloh.  ATM: expanding roles as a chief guardian of genome stability. , 2014, Experimental cell research.

[4]  T. Stankovic,et al.  The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia , 2014, Leukemia & lymphoma.

[5]  A. Shelat,et al.  Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors , 2014, Journal of biomolecular screening.

[6]  R. Yarden,et al.  BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation , 2013, Oncogene.

[7]  Gabor T. Marth,et al.  MOSAIK: A Hash-Based Algorithm for Accurate Next-Generation Sequencing Short-Read Mapping , 2013, PloS one.

[8]  Š. Pospíšilová,et al.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin , 2013, Haematologica.

[9]  Roman K. Thomas,et al.  Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors , 2013, Science Translational Medicine.

[10]  A. Pettitt,et al.  Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia , 2013, Leukemia & lymphoma.

[11]  Jun Yu,et al.  MicroRNA-18a Attenuates DNA Damage Repair through Suppressing the Expression of Ataxia Telangiectasia Mutated in Colorectal Cancer , 2013, PloS one.

[12]  M. Dyer,et al.  Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Ouillette,et al.  Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia , 2012, Genes, chromosomes & cancer.

[14]  J. Byrd,et al.  Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study , 2012, Leukemia & lymphoma.

[15]  A. Dobrovic,et al.  No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.

[16]  R. Foà,et al.  ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression , 2012, Haematologica.

[17]  M. Dyer,et al.  ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele , 2012, Haematologica.

[18]  Libing Song,et al.  miR-18a Impairs DNA Damage Response through Downregulation of Ataxia Telangiectasia Mutated (ATM) Kinase , 2011, PloS one.

[19]  M. Dyer,et al.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.

[20]  R. Gatti,et al.  ATM is down-regulated by N-Myc–regulated microRNA-421 , 2010, Proceedings of the National Academy of Sciences.

[21]  Lisa S. Chen,et al.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.

[22]  M. Dyer,et al.  A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL , 2008, Leukemia.

[23]  R. Siebert,et al.  Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yingli Sun,et al.  DNA Damage-Induced Acetylation of Lysine 3016 of ATM Activates ATM Kinase Activity , 2007, Molecular and Cellular Biology.

[25]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[26]  Lingbao Ai,et al.  Promoter hypermethylation of multiple genes in primary gastric lymphoma , 2007 .

[27]  E. Appella,et al.  Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.

[28]  Y. Shiloh,et al.  Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway , 2006, Nature Cell Biology.

[29]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[30]  Xiaofeng Jiang,et al.  A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Hutchins,et al.  Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System , 2005, Clinical Cancer Research.

[32]  D. Ginzinger,et al.  The ATM gene is a target for epigenetic silencing in locally advanced breast cancer , 2004, Oncogene.

[33]  K. Khanna,et al.  Autophosphorylation of ataxia‐telangiectasia mutated is regulated by protein phosphatase 2A , 2004, The EMBO journal.

[34]  Xiao-Fan Wang,et al.  Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation. , 2004, Genes & development.

[35]  F. Gumy-Pause,et al.  ATM gene and lymphoid malignancies , 2004, Leukemia.

[36]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[37]  M. Kastan,et al.  Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. , 2002, Genes & development.

[38]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[39]  Gabor T. Marth,et al.  A general approach to single-nucleotide polymorphism discovery , 1999, Nature Genetics.

[40]  Yosef Shiloh,et al.  Recombinant ATM protein complements the cellular A-T phenotype , 1997, Oncogene.

[41]  Y. Shiloh,et al.  Predominance of null mutations in ataxia-telangiectasia. , 1996, Human molecular genetics.

[42]  A. Taylor,et al.  Leukemia and lymphoma in ataxia telangiectasia. , 1996, Blood.

[43]  Adrian E. Raftery,et al.  mclust Version 4 for R : Normal Mixture Modeling for Model-Based Clustering , Classification , and Density Estimation , 2012 .

[44]  M. Lowery-Nordberg,et al.  Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia , 2009, Leukemia.

[45]  Lingbao Ai,et al.  Promoter hypermethylation of multiple genes in gastric lymphoma. , 2007, Leukemia & lymphoma.

[46]  K. Brown,et al.  Short Communication Ataxia-Telangiectasia-Mutated (ATM) Gene in Head and Neck Squamous Cell Carcinoma: Promoter Hypermethylation with Clinical Correlation in 100 Cases , 2004 .